Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Preliminary Results from BCG-Unresponsive NMIBC Treatment

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton May 17, 2022 12:49am

210 Views

Post# 34688232

RE:RE:RE:Preliminary Results from BCG-Unresponsive NMIBC Treatment

Hi CancerSlayer, I just reread Dr. Li's comments and I think you're right. I think 8 of the 22 patients have reached 12 months and 6 of those 8 are CR which is 75%

CancerSlayer wrote:
CancerSlayer wrote:

Eoganacht wrote: Preliminary results for a phase 2 trial of CG0070 used in conjunction with Keytruda were announced today at the AUA meeting. In the first 22 patients 8 achieved a CR at 12 months (36%) and 6 achieved a durable response (27%). As a standalone treatment in previous phase 1 and 2 trials CG0070 achieved a 12 month CR rate of just under 30%. Results seem to be very close to those of the combined use of BCG and N-803 announced on Friday.

Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC

Per CG Oncology:

Summary of Interim Clinical Results

As of the interim analysis, based on a data cutoff on April 28, 2022, 22 patients were evaluable for efficacy with a minimum of 3 months follow up.

91% of patients evaluable for efficacy (n=20/22) have achieved complete response (CR) at the initial 3-month timepoint. Of those patients evaluable for CR at additional timepoints, 87% (n=15) have also maintained a CR through 6 months, 80% (n=10) through 9 months and 75% (n=8) at the 12-month assessment.

I interpret the data differently. 75% of "evaluable" patients at 12 months (n=8) achieved a CR. I don't believe all 22 patients have reached the 12 month mark/assessment as of the date of this release.

CG0070 used as a stand-alone single agent (monotherapy) achieved a 27% CR at 12 months for CIS +/- Ta/T1 disease.

The above data certainly indicates that adding a 2nd agent to a checkpoint inhibitor (CG0070 + Keytruda) will give a much more robust response. However, there remains a big downside = too many instillations/treatments with the increased potential for poor compliance & increased side effects...not to mention cost.